Pipeline
We are advancing a portfolio of cancer therapies in various stages of preclinical and clinical development. Each candidate is structured as a separate company, a wholly owned subsidiary, with development managed centrally by the Cullinan Oncology team.
| Company | Partner | Modality / Target |
|
|||
|---|---|---|---|---|---|---|
| Pearl | Taiho | EGFR Exon 20 SM Inhibitor For NSCLC | ||||
| Amber | MIT | IL-2 and IL-12 immune stimulatory cytokine combination | ||||
| Florentine | DKFZ | FLT3 x CD3 Bispecific MAb For AML | ||||
| NexGem | Internal | HSA x CD19 x CD3 Tri-specific For ALL/NHL | ||||
| Opal | Internal | Bispecific Fusion Protein (CPI / IO Agonist) | ||||
| Jade | Fred Hutch | TCR T Cell Therapy | ||||
| MICA | PDI Therapeutics | Monoclonal antibody reinvigorating the MICA/NKG2D axis |